Synthetic Peptide Compounds for Complement Pathway Regulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for complement-mediated diseases are limited, particularly for common autoimmune and inflammatory conditions, with only two approved anti-complement therapies for orphan diseases, and there is a need for treatments that can effectively regulate the complement system to address conditions like acute intravascular hemolytic transfusion reactions, cystic fibrosis, and bacterial infections.
Innovation Solution
Development of synthetic peptide compounds that selectively inhibit classical and lectin pathway activation by binding to C1q and MBL, while leaving the alternative pathway intact, using modified peptides derived from human astrovirus protein to regulate complement activation and treat various diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If purified human C1-Inhibitor is used to treat complement-mediated diseases, then hereditary angioedema can be treated, but the therapy is limited to orphan diseases only
Solution Approach 1:
The patent develops peptide compounds that can regulate multiple complement pathways (classical and lectin pathways through C1q and MBL binding, and alternative pathway through factor B binding) to create a universal therapeutic agent applicable to various complement-mediated diseases including autoimmune diseases, inflammatory conditions, and infections, not limited to single orphan diseases
2Reliability
If eculizumab is used to inhibit C5, then paroxysmal nocturnal hemoglobinuria can be treated, but the therapy does not address other complement-mediated conditions
Solution Approach 1:
The peptide compounds are designed to interact with multiple complement components (C1q, MBL, factor B) and regulate multiple pathways simultaneously, creating a broad-spectrum therapeutic that can address diverse complement-mediated diseases beyond what single-target therapies like eculizumab can achieve
3Reliability
If current anti-complement therapies are used, then orphan diseases can be treated, but common autoimmune and inflammatory diseases remain untreated
Solution Approach 1:
The patent creates a multi-functional peptide therapeutic that can regulate all three complement pathways (classical, lectin, and alternative) through binding to key regulatory components, enabling treatment of common autoimmune and inflammatory diseases that were previously inaccessible to complement-targeted therapy
4Object-affected harmful factors
If complement activation is fully inhibited, then tissue damage is reduced, but host defense against pathogens is compromised
Solution Approach 1:
The peptide compounds exhibit pathway-selective regulation, differentially modulating the classical, lectin, and alternative pathways based on local pathological needs, allowing suppression of harmful complement-mediated tissue damage while preserving protective host defense functions against pathogens
Solution Approach 2:
The peptides regulate complement activation by binding to specific components (C1q, MBL, factor B) and modulating their activity parameters, fine-tuning the complement response to reduce tissue damage while maintaining adequate pathogen defense through controlled activation of protective pathways
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptide compounds effectively inhibit complement-mediated diseases by reducing tissue damage and inflammation, providing therapeutic benefits for conditions such as acute intravascular hemolytic transfusion reactions, cystic fibrosis, and bacterial infections, with potential applications in autoimmune diseases and viral infections.
Implementation Method 1
synthetic peptide compounds that selectively inhibit classical and lectin pathway activation by binding to C1q and MBL
Implementation Method 2
The peptides are also able to bind factor B and inhibit alternative pathway activation
Implementation Method 3
The peptide compounds effectively inhibit complement-mediated diseases by reducing tissue damage and inflammation
Data Source
AI summary
The present invention provides synthetic peptide compounds and uses thereof for therapy and diagnostics of complement-mediated diseases, such as inflammatory diseases, autoimmune diseases, and microbial and bacterial infections; and non-complement-mediated diseases, such cystic fibrosis and various acute diseases. The invention is directed to modifications of a synthetic peptide of 15 amino acids from the Polar Assortant (PA) peptide, which is a scrambled peptide derived from human Astrovirus protein. In some embodiments, the invention is directed to peptide compounds that are peptide mimetics, peptide analogs and/or synthetic derivatives of PA (e.g., sarcosine derivatives) having, for example, internal peptide substitutions, and modifications, including PEGylation at the N-terminus and C-terminus. The invention further provides methods of selecting at least one synthetic peptide for treating various conditions.